Trials / Unknown
UnknownNCT01060176
Three Dose Regimen of Tranexamic Acid in Cardiac Surgery
Three Dose Regimen of Tranexamic Acid on Blood Loss and Allogeneic Transfusions in Cardiac Surgery With Cardiopulmonary Bypass
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The current study includes patients receiving valvular replacement and coronary artery bypass surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions and clinical outcomes are recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic Acid | |
| DRUG | Saline Solution |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2019-08-01
- Completion
- 2019-12-01
- First posted
- 2010-02-02
- Last updated
- 2019-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01060176. Inclusion in this directory is not an endorsement.